These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33831240)

  • 1. Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis-authors' reply.
    Chiu SY; Chang KC; Hu TH; Chien RN
    Aliment Pharmacol Ther; 2021 May; 53(9):1042-1043. PubMed ID: 33831240
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis.
    Huang R; Liu J; Wang J; Wu C
    Aliment Pharmacol Ther; 2021 May; 53(9):1040-1041. PubMed ID: 33831236
    [No Abstract]   [Full Text] [Related]  

  • 3. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
    Goyal SK; Dixit VK; Shukla SK; Ghosh J; Behera M; Tripathi M; Gupta N; Ranjan A; Jain AK
    Indian J Gastroenterol; 2015 Jul; 34(4):286-91. PubMed ID: 26243587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B.
    Kamal F; Khan MA; Ahmed A; Nair S
    Gut; 2020 Nov; 69(11):2054-2056. PubMed ID: 32041745
    [No Abstract]   [Full Text] [Related]  

  • 5. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
    Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can tertiary prevention of hepatocellular carcinoma be achieved by nucleos(t)ide analogs therapy of hepatitis B?
    Chien RN
    J Gastroenterol Hepatol; 2011 Dec; 26(12):1699-701. PubMed ID: 22097937
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B? Authors' reply.
    Yip TC; Wong GL
    Aliment Pharmacol Ther; 2020 Jan; 51(2):315-316. PubMed ID: 31880016
    [No Abstract]   [Full Text] [Related]  

  • 8. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
    Hu TH; Yueh-Hsia Chiu S; Tseng PL; Chen CH; Lu SN; Wang JH; Hung CH; Kee KM; Lin MT; Chang KC; Lin MC; Chien RN
    Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1695-1706. PubMed ID: 33111400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
    Papatheodoridis GV; Sypsa V; Dalekos G; Yurdaydin C; van Boemmel F; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Loglio A; Siakavellas S; Gatselis N; Keskın O; Lehretz M; Savvidou S; de la Revilla J; Hansen BE; Kourikou A; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2018 Jun; 68(6):1129-1136. PubMed ID: 29427727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).
    Grossi G; Viganò M; Loglio A; Lampertico P
    Liver Int; 2017 Jan; 37 Suppl 1():45-51. PubMed ID: 28052621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply.
    Pol S; Lusivika Nzinga C; Carrat F
    Aliment Pharmacol Ther; 2021 May; 53(9):1050. PubMed ID: 33831235
    [No Abstract]   [Full Text] [Related]  

  • 12. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
    Yip TC; Wong VW; Chan HL; Tse YK; Lui GC; Wong GL
    Gastroenterology; 2020 Jan; 158(1):215-225.e6. PubMed ID: 31574268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis.
    Gu L; Yao Q; Shen Z; He Y; Ng DM; Yang T; Chen B; Chen P; Mao F; Yu Q
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1467-1476. PubMed ID: 32180249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taiwan consensus statement on the management of chronic hepatitis B.
    Chien RN; Kao JH; Peng CY; Chen CH; Liu CJ; Huang YH; Hu TH; Yang HI; Lu SN; Ni YH; Chuang WL; Lee CM; Wu JC; Chen PJ; Liaw YF
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):7-38. PubMed ID: 30527436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
    Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS
    JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.
    Zhang Z; Zhou Y; Yang J; Hu K; Huang Y
    BMC Cancer; 2019 May; 19(1):511. PubMed ID: 31142283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter to the Editor: Re: Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Kim BK; Kim SU
    Hepatology; 2021 Jan; 73(1):466. PubMed ID: 32602169
    [No Abstract]   [Full Text] [Related]  

  • 18. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis.
    Liu K; Choi J; Le A; Yip TC; Wong VW; Chan SL; Chan HL; Nguyen MH; Lim YS; Wong GL
    Aliment Pharmacol Ther; 2019 Nov; 50(9):1037-1048. PubMed ID: 31524304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B - Authors' reply.
    Tseng CH; Hsu YC; Nguyen MH
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):87-88. PubMed ID: 33444533
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
    Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
    Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.